Literature DB >> 24860870

Bevacizumab for newly diagnosed glioblastoma.

Olivier L Chinot, Wolfgang Wick, Timothy Cloughesy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24860870     DOI： 10.1056/NEJMc1403303

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

Review 1.  Antiangiogenic therapy for glioblastoma: current status and future prospects.

Authors:  Tracy T Batchelor; David A Reardon; John F de Groot; Wolfgang Wick; Michael Weller
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

Review 2.  Clinical implications of in silico mathematical modeling for glioblastoma: a critical review.

Authors:  Maria Protopapa; Anna Zygogianni; Georgios S Stamatakos; Christos Antypas; Christina Armpilia; Nikolaos K Uzunoglu; Vassilis Kouloulias
Journal:  J Neurooncol       Date:  2017-10-28       Impact factor: 4.130

3.  Predictive imaging marker of bevacizumab efficacy: perfusion MRI.

Authors:  Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-04-24       Impact factor: 12.300

Review 4.  Practical management of bevacizumab-related toxicities in glioblastoma.

Authors:  Alba A Brandes; Marco Bartolotti; Alicia Tosoni; Rosalba Poggi; Enrico Franceschi
Journal:  Oncologist       Date:  2015-01-07

5.  A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.

Authors:  Shiao-Pei Weathers; Xiaosi Han; Diane D Liu; Charles A Conrad; Mark R Gilbert; Monica E Loghin; Barbara J O'Brien; Marta Penas-Prado; Vinay K Puduvalli; Ivo Tremont-Lukats; Rivka R Colen; W K Alfred Yung; John F de Groot
Journal:  J Neurooncol       Date:  2016-07-12       Impact factor: 4.130

6.  How treatment monitoring is influencing treatment decisions in glioblastomas.

Authors:  Martha R Neagu; Raymond Y Huang; David A Reardon; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 7.  Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.

Authors:  Christie M Lincoln; Peter Fata; Susan Sotardi; Michael Pohlen; Tomas Uribe; Jacqueline A Bello
Journal:  Br J Radiol       Date:  2017-11-03       Impact factor: 3.039

Review 8.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.

Authors:  D H Heiland; W Masalha; P Franco; M R Machein; A Weyerbrock
Journal:  J Neurooncol       Date:  2015-11-27       Impact factor: 4.130

Review 10.  Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Treat Options Oncol       Date:  2014-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.